Added-value of spasticity reduction to improve arm-hand skill performance in sub-acute stroke patients with a moderately to severely affected arm-hand.
Johan Anton Franck, Rob Johannes Elise Marie Smeets, Jule Elmanowski and 2 others
PMID 33814471WHAT IT FOUND
Adding botulinum toxin to standard arm-hand therapy showed no group-level benefit once spontaneous recovery was accounted for.
However, individual results varied: three patients improved arm capacity, seven improved function, and three showed no benefit, suggesting patient selection is key.
Key findings
01At the group level, after correcting for baseline trends (spontaneous recovery and standard therapy), there were no significant differences in arm-hand skill performance or function between the pre-injection, injection, and follow-up phases.
02At the individual level, three out of ten participants showed significant additional improvements in arm-hand capacity after the injection, while seven showed improvements in arm-hand function.
03Patients who did not show significant capacity improvements had low initial motor recovery scores and wrist/hand spasticity, suggesting the injection may have temporarily reduced the muscle function needed for training progress.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Small sample size (10 patients) limits generalizability. Linear detrending may have underestimated the true effect of the botulinum toxin by overestimating spontaneous recovery. No control group receiving placebo injections; all patients received the same active treatment. All participants were male. The study design makes it difficult to separate the effects of the injection from the ongoing rehabilitation.
Declared interests
No specific funding sources or conflicts of interest are declared in the provided text.
The easy way to misread this
Do not conclude that botulinum toxin is ineffective based on the null group-level results. The study used a complex statistical correction (linear detrending) that the authors admit may have underestimated the drug's effect. Individual patient data showed that some participants did benefit, so the lack of group significance does not rule out clinical utility for specific subgroups.